ArticleActa pharmaceutica Sinica. B2022
Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Emerging and underexplored ginsenosides in cancer therapy (2020-2025): Beyond cytotoxic mechanisms.Journal of ginseng research · 2026Review
- Engineering a yeast cell factory for high-level production of unnatural ginsenoside 3β-O-Glc-DM.Microbial cell factories · 2026Article
- Sustainable Production of Ginsenosides: Advances in Biosynthesis and Metabolic Engineering.Plants (Basel, Switzerland) · 2025Review
- Developments and Applications of Liver-on-a-Chip Technology-Current Status and Future Prospects.Biomedicines · 2025Review
- Establishing cell suitability for high-level production of licorice triterpenoids in yeast.Acta pharmaceutica Sinica. B · 2024Article
- Sustainable production of natural products using synthetic biology: Ginsenosides.Journal of ginseng research · 2024Review
- Effect of anti-skin disorders of ginsenosides- A Systematic Review.Journal of ginseng research · 2023Review
- Manipulation of IME4 expression, a global regulation strategy for metabolic engineering inActa pharmaceutica Sinica. B · 2023Article
- Advances in the biosynthesis and metabolic engineering of rare ginsenosides.Applied microbiology and biotechnology · 2023Review
- Advances in the optimization of central carbon metabolism in metabolic engineering.Microbial cell factories · 2023Review
- Production of a Novel Protopanaxatriol-Type Ginsenoside by Yeast Cell Factories.Bioengineering (Basel, Switzerland) · 2023Article
- Microorganisms for Ginsenosides Biosynthesis: Recent Progress, Challenges, and Perspectives.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both natural ginsenoside F2 and unnatural ginsenoside 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.